Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 20:S0092-8674(25)01238-3.
doi: 10.1016/j.cell.2025.10.034. Online ahead of print.

Elucidating pathway-selective biased CCKBR agonism for Alzheimer's disease treatment

Affiliations

Elucidating pathway-selective biased CCKBR agonism for Alzheimer's disease treatment

Jia-Le Wang et al. Cell. .

Abstract

Expressed in the entorhinal cortex (EC), the cholecystokinin (CCK) B receptor (CCKBR) plays an important role in memory and learning. Here, we identify that CCKBR-Gs and -Gq signaling, rather than CCKBR-Gi signaling, are beneficial for Alzheimer's disease (AD) treatment. Clinically, patients with more severe AD associated with lower CCKBR-Gq activity. The cryo-electron microscopy (cryo-EM) structures of CCKBR in complex with the endogenous agonist sulfated CCK8 (CCK8s) and 3 different G protein subtypes revealed that distinct receptor conformations contribute to selective G protein bias. Leveraging these structural insights, we rationally develop synthetic CCKBR agonists, including a Gi-biased agonist (z-44) and a Gq-biased agonist (3r1). Notably, 3r1 demonstrates therapeutic potential by ameliorating cognitive decline in 5×FAD mice, reducing the number of amyloid-β plaques, and promoting long-term potentiation (LTP) via upregulation of the α-secretase (ADAM10) and the calcium signaling molecule PLCB4. Our findings suggest that synthetic biased agonists targeting CCKBR-Gq signaling have therapeutic potential for AD.

Keywords: Alzheimer's disease; CCKBR; PLC; biased agonists; cognitive enhancement; cryo-EM structure; inflammation; neuroprotection; structure-based drug design; synaptic plasticity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

LinkOut - more resources